Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
FDA Approves New Drug to Treat Psoriasis
Vowel Acoustics in Parkinson's disease and Multiple Sclerosis: Comparison of Clear, Loud and Slow Speaking Conditions.
A standardized motor imagery introduction program (MIIP) for neuro-rehabilitation: development and evaluation.
Epithelial v-like antigen mediates efficacy of anti-alpha4 integrin treatment in a mouse model of multiple sclerosis.
FDA Drug Safety Communication: FDA investigating rare brain infection in patient taking Gilenya (fingolimod)
Does jcv antibody positivity encourage cessation of natalizumab therapy in multiple sclerosis?
Vitamin D and multiple sclerosis.
Disease-specific molecular events in cortical multiple sclerosis lesions.
Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
The ICF as a framework to collect and interpret data on the extent and variety of disability in neurological conditions.
Longitudinal association between depressive symptoms and walking impairment in people with relapsing-remitting multiple sclerosis.
The Gut Microbiome and the Brain.
Central Nervous System Idiopathic Inflammatory Demyelinating Disorders in South Americans: A Descriptive, Multicenter, Cross-Sectional Study.
New Data Show Longer Tysabri Dosing Interval in MS Is Feasible
Efficacy of exercise intervention programs on cognition in people suffering from multiple sclerosis, stroke and Parkinson's disease: A systematic review and meta-analysis of current evidence.
Modulators of Microglia: a Patent Review.
Hypomethylating Agent 5-Aza-2'-deoxycytidine (DAC) Ameliorates Multiple Sclerosis in Mouse Models.
A Comparison of Supervised Machine Learning Algorithms and Feature Vectors for MS Lesion Segmentation Using Multimodal Structural MRI.
Mesenchymal Stem Cell-Based Therapy in a Mouse Model of Experimental Autoimmune Encephalomyelitis (EAE).
Acute hypercalcemia following excessive calcium supplementation in a dehydrated patient with progressive multiple sclerosis: vitamin d supplementation is a red herring.
Personalized medicine in multiple sclerosis: hope or reality?
Childhood transverse myelitis and its mimics.
Optic Nerve and its Arterial-Venous Vascularization: An Ultrasonologic Study in Multiple Sclerosis Patients and Healthy Controls.
Sphingolipids in neuroinflammation.
Determinants of disability using count-based approaches to icf-based definition of neurological disability.
Pages
« first
‹ previous
…
312
313
314
315
316
317
318
319
320
…
next ›
last »